Unlocking the biology of the brain is a research imperative that has garnered much attention from public and private entities in recent years. For example, the BRAIN Initiative and EU Initiative (humanbrainproject.eu) are focused on innovative research and technology that increases our understanding of the brain. Neurodegenerative diseases already constitute a public health and economic crisis, and as the population ages, the urgent need for better treatments for these diseases is intensified. With the acquisition of the Covance antibody product portfolio, BioLegend signaled its commitment to enabling legendary discovery within the neuroscience research community. BioLegend is making further investments in the portfolio, becoming a leading provider of reagents known for quality and innovation, and helping scientists advance the understanding of brain biology, interrogate their pathways, and identify potential biomarkers that may improve the success of clinical programs for neurodegenerative diseases.